Latest Breaking News On - National oncology research center - Page 1 : comparemela.com

Tarlatamab active in previously treated small cell lung cancer

Tarlatamab active in previously treated small cell lung cancer
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Luis pazEuropean society for medical oncology congressNational oncology research centerEuropean societyMedical oncology congressNew engand journalLuis paz aresHospital universitario

AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER

AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPuerto ricoLuniversidad complutenseJessica akopyanDavidm reeseJustin claeysLuis pazNational oncology research centerKyowa kirin co ltdTeneobio incAmerican cancer societyExchange commissionChemocentryx incWorld health organizationBeigene ltdOncology department

Dr Paz-Ares on Tusamitamab Ravtansine in CEACAM5-Positive NSCLC

Dr Paz-Ares on Tusamitamab Ravtansine in CEACAM5-Positive NSCLC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Luis pazLuniversidad complutenseNational oncology research centerOncology departmentLuis paz aresMedical oncology departmentHospital doce de octubreLung cancer unit

Dr Paz-Ares on the Challenges of NGS in NSCLC

Luis G. Paz-Ares, MD, PhD, discusses the importance of next-generation sequencing and highlights current challenges with NGS for patients with non–small cell lung cancer.

Luisg pazOncology departmentNational oncology research centerMedical oncology departmentHospital universitarioUniversidad complutense de madridLung cancer unitOnclive tvLung cancerNext generation sequencing

Cantargia AB: Cantargia to host R&D Day on nadunolimab combinational synergy in pancreatic cancer and non-small cell lung cancer

STOCKHOLM, June 9, 2022 /PRNewswire/ Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day on Thursday, June 16, 2022 at 09:00 AM EDT (3:00 PM CET), focusing

Region flamandeUnited statesLos angelesSudheer dossPrnewswire cantargiaLuniversidad complutenseLuis pazEric van cutsemVan cutsemUniversity of californiaBelgian foundationUniversity of warsawOncology departmentUniversity hospitals gasthuisbergNational oncology research centerPancreatic cancer action network pan